(Q37933395)

25 August 2017

1 reference

title

Inhibitors of cathepsin K: a patent review (2004 - 2010). (English)

1 reference

25 August 2017

Jac Wijkmans

1

1 reference

25 August 2017

Jan Gossen

series ordinal

2

1 reference

25 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Expert Opinion on Therapeutic Patents

25 August 2017

published in

1 reference

25 August 2017

volume

21

1 reference

25 August 2017

issue

10

1 reference

25 August 2017

page(s)

1611-1629

1 reference

Cysteine cathepsin S as an immunomodulatory target: present and future trends.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Cathepsin K inhibitors: a novel target for osteoporosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Cathepsin K in adipocyte differentiation and its potential role in the pathogenesis of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Bone resorption by osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Conformational flexibility and allosteric regulation of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Crystal structure of human cathepsin K complexed with a potent inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

11 Years of cyanopyrrolidines as DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Molecular recognition of ligands in dipeptidyl peptidase IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Development of nitrile-based peptidic inhibitors of cysteine cathepsins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Design of cathepsin K inhibitors for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Cathepsin K inhibitors for osteoporosis and potential off-target effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Covalent modifiers: an orthogonal approach to drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

The pH dependencies of individual rate constants in papain-catalyzed reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

The consequences of lysosomotropism on the design of selective cathepsin K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Dipeptide nitrile inhibitors of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Identification of a potent and selective non-basic cathepsin K inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Beta-substituted cyclohexanecarboxamide cathepsin K inhibitors: modification of the 1,2-disubstituted aromatic core.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffolds: synthesis and cysteinyl proteinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Exploration of the P2-P3 SAR of aldehyde cathepsin K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Arylaminoethyl amides as inhibitors of the cysteine protease cathepsin K-investigating P1' substituents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Non-covalent cathepsin K inhibitors for the treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

4-Aminophenoxyacetic acids as a novel class of reversible cathepsin K inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Irreversible inhibitors of serine, cysteine, and threonine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERG

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2011.616283

10.1517/13543776.2011.616283

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference